Ascendis Pharma Future Growth

Future criteria checks 4/6

Ascendis Pharma is forecast to grow earnings and revenue by 16.9% and 24.4% per annum respectively. EPS is expected to grow by 15% per annum. Return on equity is forecast to be 112.9% in 3 years.

Key information

16.9%

Earnings growth rate

15.02%

EPS growth rate

Biotechs earnings growth	25.4%
Revenue growth rate	24.4%
Future return on equity	112.94%
Analyst coverage	Good
Last updated	20 May 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • May 28

Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)

Summary Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage, and reduced financing risk. Yorvipath and Yuviwel are driving robust pipeline momentum, with Yorvipath scaling rapidly in chronic hypoparathyroidism and Yuviwel poised for expansion in achondroplasia. The next 12–18 months are catalyst-rich, with regulatory, clinical, and commercial milestones supporting the self-funded growth strategy and platform expansion. Read the full article on Seeking Alpha

Analysis Article • May 15

Statutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position

We didn't see Ascendis Pharma A/S' ( NASDAQ:ASND ) stock surge when it reported robust earnings recently. We think that...

New Narrative • May 07

Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability

Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long-acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?

New Narrative • Apr 21

Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years

Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?

Earnings and Revenue Growth Forecasts

NasdaqGS:ASND - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	2,397	959	589	1,097	12
12/31/2027	1,942	640	690	835	15
12/31/2026	1,339	925	349	858	15
3/31/2026	866	496	45	60	N/A
12/31/2025	720	-228	45	54	N/A
9/30/2025	647	-233	-112	-107	N/A
6/30/2025	491	-271	-171	-165	N/A
3/31/2025	369	-342	-221	-219	N/A
12/31/2024	364	-378	-308	-306	N/A
9/30/2024	327	-426	-262	-261	N/A
6/30/2024	318	-490	-332	-330	N/A
3/31/2024	329	-502	-423	-422	N/A
12/31/2023	267	-481	-470	-467	N/A
9/30/2023	152	-602	-573	-567	N/A
6/30/2023	119	-609	-549	-541	N/A
3/31/2023	78	-569	-524	-512	N/A
1/1/2023	51	-583	-510	-496	N/A
9/30/2022	33	-482	-493	-477	N/A
6/30/2022	19	-393	-500	-476	N/A
3/31/2022	14	-446	-490	-467	N/A
12/31/2021	8	-384	-442	-418	N/A
9/30/2021	3	-416	-409	-385	N/A
6/30/2021	5	-458	-364	-345	N/A
3/31/2021	5	-418	-306	-286	N/A
12/31/2020	7	-419	-293	-272	N/A
9/30/2020	9	-360	-248	-230	N/A
6/30/2020	8	-264	-246	-233	N/A
3/31/2020	10	-228	-191	-182	N/A
12/31/2019	13	-218	N/A	-176	N/A
9/30/2019	21	-170	N/A	-162	N/A
6/30/2019	19	-178	N/A	-149	N/A
3/31/2019	16	-142	N/A	-163	N/A
12/31/2018	11	-130	N/A	-139	N/A
9/30/2018	0	-132	N/A	-127	N/A
6/30/2018	1	-132	N/A	-107	N/A
3/31/2018	1	-140	N/A	-111	N/A
12/31/2017	2	-124	N/A	-95	N/A
9/30/2017	2	-106	N/A	-88	N/A
6/30/2017	3	-91	N/A	-78	N/A
3/31/2017	4	-73	N/A	-67	N/A
12/31/2016	5	-69	N/A	-60	N/A
9/30/2016	6	-64	N/A	-54	N/A
6/30/2016	6	-53	N/A	-50	N/A
3/31/2016	7	-55	N/A	-51	N/A
12/31/2015	8	-33	N/A	-43	N/A
9/30/2015	9	-26	N/A	-41	N/A
6/30/2015	10	-21	N/A	-32	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ASND's forecast earnings growth (16.9% per year) is above the savings rate (3.5%).

Earnings vs Market: ASND's earnings (16.9% per year) are forecast to grow slower than the US market (17% per year).

High Growth Earnings: ASND's earnings are forecast to grow, but not significantly.

Revenue vs Market: ASND's revenue (24.4% per year) is forecast to grow faster than the US market (11.9% per year).

High Growth Revenue: ASND's revenue (24.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ASND's Return on Equity is forecast to be very high in 3 years time (112.9%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/01 16:56
End of Day Share Price	2026/05/29 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascendis Pharma A/S is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eliana Merle	Barclays
Tazeen Ahmad	BofA Global Research
Michelle Gilson	Canaccord Genuity